KRAS and non-small cell lung carcinoma: In CodeBreak 100, a phase II trial of sotorasib monotherapy for patients with KRAS G12C mutated advanced NSCLC, previously treated with standard therapies, an objective response rate (ORR) of 37.1% with median progression-free survival (mPFS) of 6.8 months were observed.